The U.S. Food and Drug Administration today approved Axumin, a radioactive diagnostic agent for injection. Axumin is indicated for positron emission tomography (PET) imaging in men with suspected ...
U.S. FDA Approves Blue Earth Diagnostics’ Axumin™ (Fluciclovine F 18) Injection after Priority Review for PET Imaging of Recurrent Prostate Cancer - First FDA-Approved F18 PET Imaging Agent Indicated ...
BURLINGTON, Mass. & OXFORD, England--(BUSINESS WIRE)--Blue Earth Diagnostics, a Bracco company focused on molecular imaging diagnostics, today announced results from an investigational clinical trial ...
A new effective PET/CT scan for prostate cancer patients can detect the location and extent of cancer that has recurred after initial treatment. Prostate PET/CT scans can detect cancer earlier than ...
A phase 3 study from molecular imaging firm Blue Earth Diagnostics found that its Axumin contrast agent for PET scans could assist in the diagnosis of patients with glioma. Axumin, consisting of the ...
Loyola Medicine is the first center in the Midwest to offer the first effective PET/CT scan for prostate cancer patients. The scan can detect the location and extent of cancer that has recurred after ...
A positron emission tomography (PET) scan is an imaging technique that uses small amounts of radioactive substances. Doctors may use PET scans in chemotherapy treatments for cancer. PET scans help ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback